PlumX Metrics
Embed PlumX Metrics

In vitro inhibition of human cytochrome P450 enzymes by licoisoflavone B from Glycyrrhiza uralensis Fisch. ex DC

Toxicological Sciences, ISSN: 1096-0929, Vol: 196, Issue: 1, Page: 16-24
2023
  • 1
    Citations
  • 0
    Usage
  • 2
    Captures
  • 1
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Most Recent News

ToxSci November 2023 Issue Available

The November 2023 issue of Toxicological Sciences includes #ToxSpotlight articles that examine the renal proximal tubule microphysiological system as an in vitro model for drug

Article Description

Glycyrrhiza uralensis Fisch. ex DC, one of the 3 pharmacopeial species of licorice and widely used in dietary supplements, can inhibit certain cytochrome P450 (CYP) enzymes. Thereby, G. uralensis preparations have the potential to cause pharmacokinetic drug interactions when consumed along with prescription medicines. One compound (1.34 mg dry weight) responsible for inhibiting CYP2B6, CYP2C8, and CYP2C9 was isolated using bioactivity-guided fractionation from 250 g dried roots, stolons, and rhizomes. The enzyme kinetics and mechanisms of inhibition were determined using human liver microsomes, recombinant enzymes, and UHPLC-MS/MS-based assays. Identified as licoisoflavone B, this compound displayed reversible inhibition of CYP2C8 with an IC value of 7.4 ± 1.1 μM and reversible inhibition of CYP2C9 with an IC value of 4.9 ± 0.4 μM. The enzyme kinetics indicated that the mechanism of inhibition was competitive for recombinant CYP2C8, with a K value of 7.0 ± 0.7 μM, and mixed-type inhibition for recombinant CYP2C9, with a K value of 1.2 ± 0.2 μM. Licoisoflavone B moderately inhibited CYP2B6 through a combination of irreversible and reversible mechanisms with an IC value of 16.0 ± 3.9 μM.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know